Cognitive impairment · neonates with EEG‐confirmed seizures
It is very uncertain whether summary of findings table ‐ Phenobarbital + bumetanide changes cognitive impairment at 18‐24 months compared with phenobarbital alone (very low certainty).
1 finding from 1 review
Need for mechanical ventilation · neonates with EEG‐confirmed seizures
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Proportion of infants who develop epilepsy post‐discharge · neonates with EEG‐confirmed seizures
It is very uncertain whether summary of findings table ‐ Phenobarbital + bumetanide changes proportion of infants who develop epilepsy post‐discharge compared with phenobarbital alone (very low certainty).
1 finding from 1 review
Hypertensive disorders of pregnancy: pre‐eclampsia · women with type 2 diabetes
It is very uncertain whether maternal outcomes: oral anti‐diabetic agent (metformin) changes hypertensive disorders of pregnancy: pre‐eclampsia compared with insulin (very low certainty).
1 finding from 1 review
Hypertensive disorders of pregnancy (pregnancy‐induced hypertension) · women with type 2 diabetes
Maternal outcomes: oral anti‐diabetic agent (metformin) may leads to lower hypertensive disorders of pregnancy: pregnancy‐induced hypertension compared with insulin (low certainty).
1 finding from 1 review
Caesarean section · women with type 2 diabetes
Maternal outcomes: oral anti‐diabetic agent (metformin) may leads to lower caesarean section compared with insulin (low certainty).
1 finding from 1 review
Induction of labour · women with type 2 diabetes
It is very uncertain whether maternal outcomes: oral anti‐diabetic agent (metformin) changes induction of labour compared with insulin (very low certainty).
1 finding from 1 review
Perineal trauma · women with type 2 diabetes
1 finding from 1 review
Postnatal depression · women with type 2 diabetes
1 finding from 1 review
Postnatal weight retention · women with type 2 diabetes
1 finding from 1 review
Reduction in the amount of saliva production in the short term using an objective measure · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
no estimate extracted
1 participants
Very low
Quality of life · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
no estimate extracted
1 participants
Moderate
Participant‐reported improvement in sialorrhea in the short term · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
no estimate extracted
1 participants
Moderate
Retention [ · trial participants being followed up for data collection
It is very uncertain whether data collection location and method: telephone follow‐up changes retention [ compared with postal questionnaire (very low certainty).
1 finding from 1 review
Mortality Mortality at latest · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) leads to lower mortality at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower mortality or BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
1 finding from 1 review
Cerebral palsy · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Death or cerebral palsy · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in mortality or cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review